Abivax Stock: Should You Invest After Obefazimod Trial Results?

Abivax is undoubtedly one of the French biotech companies that has generated the most buzz on the stock market in 2026. The company, specializing in the development of treatments for chronic inflammatory diseases, operates in a promising yet particularly demanding market. With biotech sector stocks, expectations can change rapidly, and stock prices with them.

The Abivax share is a good example. In recent months, it has experienced impressive movements, both up and down. This volatility can certainly create opportunities, but it also reminds investors of the risks they face with this type of asset.

In this Abivax analysis, we will review Abivax’s stock market journey, its activity and its latest results. We will then look at the fundamentals of the company and the technical analysis of Abivax’s share price. Finally, we will assess whether the current stock price level for Abivax could represent an investment opportunity by the end of 2026.

Who is Abivax? History and key figures 2026

Abivax is a French clinical-stage biotech whose history today is closely linked to obefazimod (ABX464), its leading drug candidate. Its approach is to harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Obefazimod is notably being developed for moderate to severe ulcerative colitis, with a Phase 3 program reached.

Abivax thus stands at a pivotal moment in its development: still a clinical biotech, the company is progressively strengthening its organization to prepare for a potential commercialization of obefazimod. This evolution has also given Abivax’s stock a new dimension, now listed on both the French and the American markets.

Key information about Abivax

Abivax has been listed on Euronext Paris since June 2015 and on the Nasdaq Global Market since October 2023. Its entry into the SBF 120 and the CAC Mid 60 dates back to September 2025.

What are Abivax’s latest results in 2026?

The results for the first half of 2026 for Abivax must be read with the particularities typical of a biotech that has not yet commercialized a drug. At this stage, the objective is not to seek revenue growth or margin improvement, but to observe the pace of research expenditures, cash burn, and Abivax’s ability to finance its clinical development through to potential commercialization.

In this respect, the first half of 2026 marks a clear acceleration of investments. R&D expenses rise sharply, notably with the advancement of clinical programs around obefazimod. Abivax is also starting to incur more commercial and administrative expenses to prepare for what comes next.

The logical consequence is that losses have increased significantly. But the balance sheet reads very differently, since the fundraising completed in early July has substantially strengthened the financial resources now available to Abivax.

Key figures of H1 2026 results for Abivax

Comment by Chris Rabbat, Chief Medical Officer of Abivax :

The seven accepted abstracts* demonstrate the breadth and maturity of the obefazimod development program, covering Phase 3 maintenance results, long-term efficacy and tolerability data from Phase 2, as well as preclinical results on inflammation and fibrosis.

*Chris Rabbat refers here to the seven scientific works devoted to obefazimod that were selected to be presented at UEG Week 2026, the major European gastroenterology congress held in Barcelona in October 2026.

What is Abivax’s position in the biotech sector in 2026?

In 2026, Abivax occupies a particular position among French biotechs. The company remains at the clinical stage, but it is approaching a decisive milestone with obefazimod, its leading drug candidate. In ulcerative colitis, the Phase 3 results obtained this year have strengthened the clinical dossier, notably achieving the study’s primary endpoint and key secondary endpoints of the ABTECT maintenance study. Abivax now plans to file a marketing authorization application with the US FDA by the end of 2026.

The appeal of the pipeline does not stop at this indication. Obefazimod is also being evaluated in Crohn’s disease, with Phase 2b results expected by mid-2027.

Thus Abivax presents a profile fairly characteristic of advanced biotechs: a significant potential, but still largely focused on a single asset, which makes the upcoming clinical, regulatory, and eventually commercial steps particularly decisive.

Comment by Marc de Garidel, CEO of Abivax :

As we prepare Abivax for its next growth phase and the potential commercialization of obefazimod, we continue to strengthen our leadership team and the skills needed to support this evolution.

Should you invest in Abivax stock in 2026? Our view and fundamental analysis

The fundamental analysis of Abivax largely deviates from standard measures. A PER or an EBITDA multiple makes little sense today, since the company has not yet commercialized its lead drug candidate and remains structurally unprofitable. Abivax’s stock valuation therefore rests mainly on the prospects for obefazimod and the probability that its clinical development ultimately translates into commercial success.

This precisely explains a high price-to-book ratio despite a now very solid balance sheet. The July fundraising also profoundly changes Abivax’s financial profile: with about €1.17 billion of cash on a pro forma basis and almost no financial debt, the risk of near-term refinancing has been substantially reduced.

Abivax estimates it has financial visibility through the fourth quarter of 2029. For the investor, the main risk is therefore no longer immediately financial: it is primarily clinical, regulatory, and then commercial.

Summary Table of Abivax’s Key Financial Indicators

Note: cash, net debt, equity, EV and Price-to-Book data presented in this table are calculated on a pro forma basis, incorporating to the balance sheet as of 30 June 2026 the €767.1 million net proceeds from the capital increase completed in early July 2026.

How far can Abivax stock go in 2026? Our view and technical analysis

Following the fundamental analysis of Abivax, the study of the chart provides a complementary reading of Abivax stock. In a biotech as volatile as this, technical analysis should not replace the study of clinical data and fundamentals, but it can help identify price zones where the risk-reward becomes more attractive.

Short-term technical analysis of Abivax stock

In the short term, the trend of Abivax stock remains clearly bearish. Since its high on July 3, 2026, Abivax’s stock price has fallen 44.72% and is now around €78.55. The next major technical zone sits around €63, a level that constitutes the main visible support on the chart. A return to this zone should be closely watched: a bullish reaction could allow for a rebound, while a clear breakdown would further deteriorate the technical setup.

On the upside, the first major resistance for Abivax is around €93.80. This zone is particularly interesting as it has served as support on several occasions between January and May 2026. Since its breakdown, the polarity reversal logic suggests this former support could act as a significant resistance. Above it, Abivax would encounter an intermediate zone between €109 and €115, then a major resistance around €122. Finally, €135, corresponding to the high point visible on the chart, constitutes the last major resistance.

Technical reading, however, must take into account the very peculiar profile of Abivax stock. The moves observed in recent months show extremely high volatility, notably the strong upside gap in June followed by the subsequent correction. Abivax remains a mid-cap, with market depth and liquidity not comparable to a large-cap stock. Breaks of supports and resistances can therefore be rapid and sometimes violent.

In this context, fundamentals should remain at the center of Abivax’s analysis. Technical analysis mainly complements to identify potential entry points, monitor reactions at supports, or wait for confirmation of a breakout of resistance before interpreting a change in momentum.

Abivax daily chart

Long-term technical analysis of Abivax stock

On a weekly basis, Abivax’s technical analysis confirms several levels identified on the daily chart. The major support around €63 remains the first area to watch if the decline continues. On the upside, the former support around €94 reappears, followed by major resistances around €122 and €135.

The value of the weekly chart is mainly to take more perspective. If the 63€ support gives way permanently, Abivax stock would enter a zone that has seen much less activity recently. A first long-term support appears around €36.20. Further down, the zone around €19.70 constitutes the last clearly identifiable major support on this chart. These levels remain well away from the current price and correspond more to scenarios of sharp deterioration than to price targets.

The weekly chart also helps measure the magnitude of the change in Abivax’s size. After trading at very low levels in spring 2025, the price experienced a dramatic breakout in summer 2025, followed by several months in a broad range roughly between 90 and 120 €. A new acceleration in June-July 2026 then pushed Abivax to around 135 €, prior to the current correction.

In the long term, 63 € appears to be the true pivot level. Its preservation would leave intact a large portion of the upside structure begun in 2025. Conversely, a confirmed break at weekly close would significantly weaken the chart pattern and progressively bring zones of 36.20 €, then potentially 19.70 €, back onto investors’ radar.

Abivax weekly chart

Key technical levels to watch on Abivax stock

Should you buy Abivax stock in 2026? Café de la Bourse view

In our view, Abivax stock could be of interest by the end of 2026 for an investor who accepts a high level of risk and who believes in the commercial potential of obefazimod. The investment case has shifted in dimension as Abivax moves closer to a potential commercialization phase and now has substantial financial resources to continue its development, with visibility through the fourth quarter of 2029. Most importantly, Abivax’s valuation today rests less on its current financial results than on the future revenues that obefazimod could generate if it obtains the necessary approvals and achieves the anticipated commercial success.

However, despite the progress made, Abivax remains a loss-making biotech whose multi-billion euro valuation already incorporates substantial expectations. A regulatory setback, disappointing clinical data for a new indication, or later, a less dynamic commercialization than expected could seriously challenge this valuation.

Therefore, Abivax stock seems more suited to a satellite and measured position within a diversified stock portfolio than to a central exposure.

How to invest in Abivax stock in practice?

The most direct way to invest in Abivax remains to buy Abivax stock on the market. From an ordinary brokerage account (CTO), it is accessible through stock brokers such as IG, eToro or Freedom24. Abivax stock is also eligible for a PEA, so French investors can favor this tax wrapper with online brokers offering the PEA such as XTB, Trade Republic or ProRealTime x Interactive Brokers.

Direct investment seems particularly relevant for an investor who wants to position themselves in Abivax stock. As a mid-cap, the company can enter the composition of some ETFs, but its weight will generally remain limited compared to large international sector stocks. To obtain real exposure to Abivax stock, direct purchase therefore appears to be the simplest solution.

It is however possible to complement this position with a biotech-focused ETF to diversify sector exposure and reduce risk slightly. Among UCITS ETFs available to European investors, for example, one can cite the Global X Genomics & Biotechnology UCITS ETF (ISIN IE00BM8R0N95) or the WisdomTree BioRevolution UCITS ETF USD Acc (ISIN IE000O8KMPM1), typically available from brokers such as Saxo Bank or Bourse Direct, for example.

One approach could be, for example, to allocate 10 to 20% of the desired biotech exposure to Abivax stock directly and invest the remainder in a diversified biotech ETF. This way the investor retains specific exposure to Abivax’s potential while reducing dependence on the clinical and commercial results of a single biotech. Remember once again that investing in biotech stocks is highly speculative and carries significant risk.

The information from Cafedelabourse.com and its publications is provided for educational purposes. It does not constitute investment recommendations. Readers should study the risks before making any transaction. They are solely responsible for their investment decisions.

Past performance is not indicative of future results. Investing in stocks carries the risk of capital loss.

All information is, by nature, generic. It does not take into account your personal situation and does not constitute personalized investment advice in any way, nor an invitation to buy or sell financial instruments. The reader is solely responsible for the use of the information provided, and there is no recourse against Cafedelabourse.com’s publisher. The publisher’s liability cannot be engaged in the event of an error, omission, or ill-timed investment.